Patent · US Active

Anti-Siglec-5 antibodies and methods of use thereof

US11965023B2 · kind B2 · utility

1Cited by

59References

32Claims

0Family size

Assignee

Alector LLC

Inventors

Kate Monroe · Berkeley, US
Helen LAM · Union City, US
Patricia Culp · Oakland, US
Arnon Rosenthal · Woodside, US

Key dates

Filing date	May 9, 2022
Grant date	Apr 23, 2024
Priority date	—
Expiry date	May 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.